Comparative study of equine bone marrow and adipose tissue‐derived mesenchymal stromal cells

Ranera, B.; Ordovás, Laura; Lyahyai, Jaber; Bernal, María Luisa; Fernandes, Fernanda Dreux Miranda; Remacha, Ana Rosa; Romero, Antonio; Vázquez, Francisco José; Osta, Rosario; Cons, C.; Varona, L.; Zaragoza, Pilar; Martín-Burriel, Inmaculada; Rodellar, Clementina

doi:10.1111/j.2042-3306.2010.00353.x

Cited by 54 publications

(67 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, HAMα cells had excellent proliferative ability, and their average population doubling time was 46.53 ±5.16 h in passage 5. These results indicated that HAMα cells possessed similar properties to MSCs derived from other tissues in previous studies [12,20,22,25,26]. We are currently in the process of obtaining more series of HAMα cells with improved efficiency.…”

Section: Discussionsupporting

confidence: 72%

“…HAMα cells derived from all the donors showed excellent potential for osteogenic differentiation. Although direct comparative study was not performed in this study, the differentiation ability of HAMα cells was comparable to that of MSCs derived from other tissues, with regard to ALP activity and OCN gene expression [22,23,[25][26][27][28]. In MSCs derived from the bone marrow, the effect of donor age or cell generation time on cell proliferation and differentiation has been discussed [12,14,15,25].…”

Section: Discussionmentioning

confidence: 61%

See 1 more Smart Citation

Application of human amniotic mesenchymal cells as an allogeneic transplantation cell source in bone regenerative therapy

Tsuno

Yoshida

Nogami

et al. 2012

Materials Science and Engineering: C

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 72%

Section: Discussionmentioning

confidence: 61%

Application of human amniotic mesenchymal cells as an allogeneic transplantation cell source in bone regenerative therapy

Tsuno

Yoshida

Nogami

et al. 2012

Materials Science and Engineering: C

View full text Add to dashboard Cite

“…Rabbit serum has a high content in free fatty acids, which are putative ligands of peroxisome proliferator-activated Receptor gamma and may thus enhance adipogenesis. Recently, Ranera et al [47], comparing different induction media for adipogenic differentiation of equine MSCs, found that only the medium supplemented with 15% rabbit serum was able to induce adipogenic differentiation. However, other authors demonstrated that incubation with rabbit serum for a long period, however, can lead to cell detachment [48].…”

Section: Discussionmentioning

confidence: 98%

Equine Bone Marrow and Adipose Tissue Mesenchymal Stem Cells: Cytofluorimetric Characterization, In Vitro Differentiation, and Clinical Application

Iacono

Merlo

Romagnoli

et al. 2015

Journal of Equine Veterinary Science

View full text Add to dashboard Cite

a b s t r a c tThe aim of the present work was to isolate, cultivate, differentiate, and conduct cellular characterization of mesenchymal stem cells (MSCs) derived from equine adipose tissue (eAT) and bone marrow (eBM). Isolated and characterized cells were used in racehorses suffering from a superficial flexor tendon injury. Equine adipose tissue collection was performed at the base of the horse tail, whereas eBM was aspirated from iliac crest. Mononuclear cell fraction was isolated and cultured. In vitro differentiation and molecular characterization at P3 of culture were performed. No statistically significant differences in the number of cell doublings were found among different culture passages (P > .05). Doubling time was greater for eBM than eAT (3.2 AE 1.5 vs. 1.3 AE 0.7; P < .05). Positive von Kossa and Alizarin Red staining confirmed osteogenesis. Alcian Blue and Oil Red O staining illustrated chondrogenesis and adipogenesis, respectively. Isolated cells resulted positive for CD90, CD44, and CD105, whereas negative for hematopoietic markers, CD14, CD45, and CD34. Using isolated cells for injured tendon therapy, no adverse reactions were observed, and all inoculated horses returned to race competitions. In vitro results revealed the immunophenotypic characterization of isolated cells similar to that observed in human MSCs from the same sources; furthermore, in the present study, their clinical use proves the safety of eBM-derived and eAT-derived MSCs and a successful outcome for the treated animals that returned to their previous level of sport activity.

show abstract

“…Therefore, several markers have been tested and used, such as the positive markers CD44, CD90 CD29 [11,15,17,20], CD105 [21-23], MHC-I [5,15,20] and the negative markers CD14 [17], CD34 [21,23], MHC-II [5,17,20,23,24], CD45 [21,24], based on minimal criteria established by the International Society for Cellular Therapy (ISCT) to define human MSCs [25] and adipose-tissue derived stromal/stem cells [26]. …”

Section: Introductionmentioning

confidence: 99%

Equine mesenchymal stem cells from bone marrow, adipose tissue and umbilical cord: immunophenotypic characterization and differentiation potential

et al. 2014

View full text Add to dashboard Cite

IntroductionStudies with mesenchymal stem cells (MSCs) are increasing due to their immunomodulatory, anti-inflammatory and tissue regenerative properties. However, there is still no agreement about the best source of equine MSCs for a bank for allogeneic therapy. The aim of this study was to evaluate the cell culture and immunophenotypic characteristics and differentiation potential of equine MSCs from bone marrow (BM-MSCs), adipose tissue (AT-MSCs) and umbilical cord (UC-MSCs) under identical in vitro conditions, to compare these sources for research or an allogeneic therapy cell bank.MethodsThe BM-MSCs, AT-MSCs and UC-MSCs were cultured and evaluated in vitro for their osteogenic, adipogenic and chondrogenic differentiation potential. Additionally, MSCs were assessed for CD105, CD44, CD34, CD90 and MHC-II markers by flow cytometry, and MHC-II was also assessed by immunocytochemistry. To interpret the flow cytometry results, statistical analysis was performed using ANOVA.ResultsThe harvesting and culturing procedures of BM-MSCs, AT-MSCs and UC-MSCs were feasible, with an average cell growth until the third passage of 25 days for BM-MSCs, 15 days for AT-MSCs and 26 days for UC-MSCs. MSCs from all sources were able to differentiate into osteogenic (after 10 days for BM-MSCs and AT-MSCs and 15 days for UC-MSCs), adipogenic (after 8 days for BM-MSCs and AT-MSCs and 15 days for UC-MSCs) and chondrogenic (after 21 days for BM-MSCs, AT-MSCs and UC-MSCs) lineages. MSCs showed high expression of CD105, CD44 and CD90 and low or negative expression of CD34 and MHC-II. The MHC-II was not detected by immunocytochemistry techniques in any of the MSCs studied.ConclusionsThe BM, AT and UC are feasible sources for harvesting equine MSCs, and their immunophenotypic and multipotency characteristics attained minimal criteria for defining MSCs. Due to the low expression of MHC-II by MSCs, all of the sources could be used in clinical trials involving allogeneic therapy in horses. However, the BM-MSCs and AT-MSCs showed fastest ‘‘in vitro’’ differentiation and AT-MSCs showed highest cell growth until third passage. These findings suggest that BM and AT may be preferable for cell banking purposes.

show abstract

Comparative study of equine bone marrow and adipose tissue‐derived mesenchymal stromal cells

Abstract: To provide data to better understand AT-MSCs and BM-MSCs behaviour in vitro.

Cited by 54 publications

References 47 publications

Application of human amniotic mesenchymal cells as an allogeneic transplantation cell source in bone regenerative therapy

Application of human amniotic mesenchymal cells as an allogeneic transplantation cell source in bone regenerative therapy

Equine Bone Marrow and Adipose Tissue Mesenchymal Stem Cells: Cytofluorimetric Characterization, In Vitro Differentiation, and Clinical Application

Equine mesenchymal stem cells from bone marrow, adipose tissue and umbilical cord: immunophenotypic characterization and differentiation potential

Contact Info

Product

Resources

About